Annamaria Brioli

Hannover, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Disrupting adaptive proteostasis to overcome proteasome inhibitor resistance.

Disrupting adaptive proteostasis to overcome proteasome inhibitor resistance.

Journal: Haematologica

Published: February 24, 2026

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

Journal: British journal of cancer

Published: January 03, 2026

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Journal: Leukemia

Published: December 06, 2025

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Journal: American journal of hematology

Published: December 02, 2025

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Journal: Blood cancer journal

Published: November 08, 2025

The role of the bone marrow microenvironment in disease progression and drug resistance in multiple myeloma in the era of novel agents.

The role of the bone marrow microenvironment in disease progression and drug resistance in multiple myeloma in the era of novel agents.

Journal: Leukemia & lymphoma

Published: November 03, 2025

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.

Journal: Leukemia

Published: October 30, 2025

Association of retinoids, retinoic acid receptors and epigenetics in breast cancer.

Association of retinoids, retinoic acid receptors and epigenetics in breast cancer.

Journal: Oncogene

Published: October 30, 2025

Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.

Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.

Journal: Leukemia

Published: October 18, 2025

Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report.

Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report.

Journal: Annals of hematology

Published: April 20, 2025

Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression.

Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression.

Journal: BMC cancer

Published: February 11, 2025

Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.

Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.

Journal: British journal of haematology

Published: February 03, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026